ASTM F2902-24 PDF

Full title and description

Standard Guide for Assessment of Absorbable Polymeric Implants — ASTM F2902-24. This guide provides recommendations and guidance for the chemical, physical, mechanical, biocompatibility, and preclinical assessment of implantable synthetic polymeric absorbable devices and device components, covering a range of polymer forms (solid and porous) and degradation behaviors to support R&D and regulatory submissions.

Abstract

ASTM F2902-24 is a non‑prescriptive guide intended to assist manufacturers and researchers in selecting and performing appropriate characterization and preclinical evaluations for absorbable polymeric implants. It highlights common assessment approaches for raw materials through finished components, notes limitations when polymers are blended or combined with other substances, and recommends conformity with applicable regulatory test practices (for example, FDA GLP where feasible). The guide is written with emphasis on hydrolytically degradable synthetic polymers but provides principles that may be adapted for other systems.

General information

• Status: Current / Active.
• Publication date: October 15, 2024.
• Publisher: ASTM International.
• ICS / categories: 11.040.40 (Implants for surgery; prosthetics and orthotics).
• Edition / version: F2902-24 (2024 edition).
• Number of pages: 17.

Scope

This guide describes general guidelines and suggested evaluation methods for the chemical, physical, mechanical, biocompatibility, and preclinical assessment of implantable synthetic polymeric absorbable devices and components. It is intended to cover a broad array of absorbable polymeric forms (including injection‑molded solids and porous/fibrous constructs) and is principally focused on polymers that degrade in vivo primarily by hydrolysis. The guide recommends using appropriate ASTM, ISO, and regulatory test methods as needed and notes that application‑specific testing (orthopedic, cardiovascular, sutures, drug‑release matrices, etc.) may require additional evaluations beyond this guide. SI units are used throughout.

Key topics and requirements

• Chemical characterization of polymer composition and residuals (additives, catalysts, monomers).
• Physical and morphological analyses (crystallinity, porosity, surface texture, molecular weight distribution).
• Mechanical testing relevant to intended use (strength, modulus, fatigue, fixation performance).
• Degradation assessment: in vitro hydrolysis studies, degradation rate profiling, identification of degradation products and kinetics.
• Biocompatibility and toxicology screening in accordance with recognized guidance (e.g., ISO 10993 series) and consideration of composite interactions when materials are blended or coated.
• Preclinical evaluation strategies including relevant in vivo models and end points to support clinical translation and regulatory filings.
• Recommendations to follow applicable regulatory laboratory practices (for example, FDA GLP where feasible) and to align assessments with submission pathways (IDE, PMA, 510(k), CE as appropriate).
• Notes on the limits of preclinical models and the need to interpret clinical relevance cautiously.

These topics reflect the guide’s emphasis on establishing a pragmatic, risk‑based test matrix from raw material through finished device.

Typical use and users

This guide is intended for medical device manufacturers, polymer formulators, research & development teams, regulatory affairs professionals, contract research organizations (CROs), and independent testing laboratories involved in the development, evaluation, and regulatory submission of absorbable polymeric implants. Clinician‑researchers and product development engineers may also use the guide to design preclinical testing strategies and to interpret material behavior in device contexts.

Related standards

Related and referenced documents commonly used alongside F2902-24 include earlier editions of the same guide (for example, ASTM F2902-16e1 and earlier F2902 revisions), the ISO 10993 series for biological evaluation of medical devices, and standards/guides for device packaging and accelerated aging such as ASTM F1980 and ISO 11607 when shelf‑life or packaging stability are relevant. Users should consult application‑specific ASTM and ISO test methods as indicated in the guide and by regulatory expectations.

Keywords

absorbable; bioabsorbable; bioresorbable; biodegradable; degradation; hydrolysis; hydrolytically degradable polymers; polymeric implants; biocompatibility; preclinical assessment; implantable devices.

FAQ

Q: What is this standard?

A: ASTM F2902-24 is a standard guide providing recommended assessments and evaluation approaches for implantable synthetic absorbable polymeric devices and their components. It is advisory (guide) rather than a mandatory test method.

Q: What does it cover?

A: It covers chemical, physical, mechanical, biocompatibility, and preclinical assessments of absorbable polymeric implants, including guidance on testing composites and blended materials, and on selecting appropriate test methods to support safety and effectiveness evaluations.

Q: Who typically uses it?

A: Device manufacturers, R&D teams, CROs, testing laboratories, regulatory professionals, and clinician‑researchers involved with absorbable implant development and regulatory submissions commonly use this guide.

Q: Is it current or superseded?

A: F2902-24 is the current (active) edition published in 2024 and replaces prior editions; users should reference the 2024 designation for the latest guidance.

Q: Is it part of a series?

A: F2902 is a standalone guide within ASTM’s medical device/biomaterials portfolio but is typically used in conjunction with related ASTM methods and international standards (for example, the ISO 10993 biocompatibility series and device packaging/aging guides such as ASTM F1980 and ISO 11607). Previous versions (e.g., F2902-16e1 and earlier) provide historical context.

Q: What are the key keywords?

A: absorbable, bioabsorbable, bioresorbable, biodegradable, hydrolysis, degradable polymers, implant, biocompatibility, preclinical assessment.